企業を読み込み中
Keep exploring
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1.36TA+
JNJJohnson & Johnson$688.6BA+
MRKMerck & Co., Inc.$364.3BA
NVSNovartis AG$306.3BA
AMGNAmgen Inc.$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- Sales of prescription medicines
- Revenue from medicine partnerships
競合
何を売っているか6
Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
さらに3件を表示
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
誰が買っているか3
- Patients receive the medicines, usually after a clinician prescribes them.
- Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
- Government health systems and private insurers may pay for or reimburse medicines.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
- 2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
- 3Sales in China are affected by government volume-based purchasing and reimbursement decisions.
うまくいかなくなる可能性
- 1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
- 2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
- 3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.
Astrazeneca plcについて
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
- 本社
- Cambridge, England, United Kingdom
- 設立
- 1992
- 上場市場
- New York Stock Exchange
- 決算期
- December 31
Astrazeneca plc 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。